ChromaDex and the Citrin Foundation Announce Global Research Collaboration Exploring Citrin Deficiency

LOS ANGELES–(BUSINESS WIRE)—- $CDXC #collaboration–ChromaDex Corp. (NASDAQ: CDXC) today announced a new research initiative with the Citrin Foundation of Singapore to study the effects of Niagen® nicotinamide riboside (NR) and citrin deficiency, a rare genetic condition. In collaboration with the ChromaDex External Research Program (CERP™) and leading research institutions, the…